E-7564 Funding for Elahere ovarian cancer treatment Petition Tracker | Signature Growth — Canadian Petition Tracker
Track E-7564 — Funding for Elahere ovarian cancer treatment — with 1,152 signatures and counting. Sponsored by Helena Jaczek. See signature growth trends and provincial breakdown on PetitionTracker.ca.
Canonical URL: https://petitiontracker.ca/petition/e-7564
Petition Details
- Status: Closed
- Closing date: August 1, 2026
- Sponsor: Helena Jaczek (Markham—Stouffville)
- Category: Health
Signature Statistics
- Total signatures: 1,152
- Daily increase: +313 in the last 24 hours
- Seven-day increase: +386 over the last 7 days
- Growth velocity: ~55 new signatures per day (7-day average)
- Tracking started: July 2, 2026 — 144 data points recorded
Milestones
- 1,000 signatures reached on August 1, 2026 — total at that point: 1,047
- Debate threshold (500 signatures) reached on July 12, 2026 — total at that point: 500
Provincial Distribution
- Ontario: 907 signatures
- Alberta: 65 signatures
- British Columbia: 51 signatures
- Manitoba: 39 signatures
- Saskatchewan: 26 signatures
- Quebec: 25 signatures
- Newfoundland and Labrador: 14 signatures
- Nova Scotia: 11 signatures
- New Brunswick: 7 signatures
- Prince Edward Island: 1 signatures
Historical Signature Growth
| Date | Signatures |
|---|
| July 2, 2026 | 22 |
| July 4, 2026 | 184 |
| July 6, 2026 | 241 |
| July 8, 2026 | 430 |
| July 10, 2026 | 487 |
| July 13, 2026 | 511 |
| July 16, 2026 | 560 |
| July 18, 2026 | 649 |
| July 20, 2026 | 722 |
| July 23, 2026 | 755 |
| July 27, 2026 | 772 |
| July 30, 2026 | 830 |
| August 1, 2026 | 1,152 |
Petition Text
Petition to the Minister of Health
Whereas:
• The public funding negotiations for Elahere (mirvetuximab soravtansine) have experienced extensive delays, after initial negotiations concluding with no agreement;
• In treating ovarian cancer, Elahere has been proven to be more effective than traditional funded chemotherapies (see study in the New England Journal of Medicine);
• Elahere has side effects that are different from traditionally used chemotherapies, which make it a better choice for many patients with underlying conditions, like Crohn's Disease; and
• Exorbitant medication costs unfairly disadvantage vulnerable communities, cutting them off from life-changing care. Citizens deserve a healthcare system that funds the most effective treatments available.
We, the undersigned, citizens of Canada, call upon the Minister of Health to instruct the pCPA (Pan-Canadian Pharmaceutical Alliance) to restart negotiations with the manufacturer of Elahere (AbbVie), with a mandate of reaching an agreement that will see Elahere become a funded treatment option for patients suffering from ovarian, fallopian tube and peritoneal cancers, across the country.
Similar Petitions